Built around the endurance training year — base phase, build, peak, and recovery. Overuse injury management is the primary application. All compounds listed are currently WADA-permitted.
The primary drivers for peptide use in endurance athletes are overuse injury management and mitochondrial efficiency. Endurance training at high volume produces repetitive microtrauma to tendons, ligaments, and connective tissue — BPC-157 and TB-500 address this directly. At the cellular level, high-volume endurance training depletes NAD+ and stresses mitochondria — SS-31 and MOTS-c address the mitochondrial side.
All compounds in this protocol are not currently listed on the WADA Prohibited List as of 2025. However, WADA updates the prohibited list annually and compounds can be added. BPC-157 and TB-500 are both under review periodically. Athletes competing under anti-doping rules should verify current WADA status before each competition year. This is non-negotiable.
The calendar is structured around a typical endurance season: base phase (January–February) — light BPC-157 and TB-500 for connective tissue maintenance; build phase (March–June) — SS-31 and MOTS-c added for mitochondrial efficiency during high-volume blocks; peak (July–August) — reduce injury risk compounds, maximise training stimulus; post-season (September–December) — recovery focus with TB-500 return and NAD+ continuous.
Endurance sport depletes iron rapidly — particularly in female athletes and heavy mileage runners. Ferritin and full iron panel are the most important blood tests for endurance athletes and should be checked at season start, peak training, and post-season. Low ferritin (below 30–40 ng/mL) dramatically impairs performance and recovery independent of haemoglobin.
Full dosing, titration schedule, blood work timing and cycling notes are available inside the platform. Use the calendar to track your protocol.